Cancer care exposes two populations to harm that ordinary clinic design does not address: staff who handle antineoplastic (hazardous) drugs every shift, and patients whose immune systems are deliberately or unavoidably suppressed. This article covers the safety program and operational infection-control perspective of activation — how the built environment, the equipment package, and the written program combine to protect both groups. It complements, rather than repeats, the compounding-room ventilation engineering covered elsewhere in this Part; here the focus is the hazardous-drug handling program end-to-end and the infection-control measures that keep neutropenic and transplant patients alive.

Hazardous-drug safety spans the entire handling chain, not just the IV room

A common design error is to treat hazardous-drug (HD) safety as a problem solved by building a USP <800> compounding suite. In reality, antineoplastic agents and other HDs travel a chain — receiving, storage, transport, compounding, administration, patient care, waste, and spill response — and every link needs engineering and program controls. USP General Chapter <800> ("Hazardous Drugs — Handling in Healthcare Settings") is the governing standard, and it explicitly applies to all personnel who handle HDs and all the spaces those drugs pass through, not only the cleanroom.

The drugs of concern are defined by the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, which a facility uses to build its own HD inventory and assessment-of-risk. The list groups drugs into antineoplastics, non-antineoplastics with hazardous characteristics, and reproductive-risk agents — categories that drive how each drug is stored, compounded, and disposed.

Design and activation implications across the chain:

• Receiving and unpacking. HDs should be received in a designated, neutral-or-negative-pressure area with spill supplies staged, never unpacked at an open clinic counter. Externally contaminated shipping containers are a known surface-contamination source.
• Storage. Antineoplastic HDs requiring manipulation are stored in a negative-pressure room with at least the ventilation USP <800> specifies for storage, separated from non-HD inventory. Refrigerated HDs need an HD-dedicated refrigerator located in (or exhausted from) a negative-pressure space — a frequently missed program-equipment item.
• Transport. HDs move in sealed, labeled, leak-proof containers, never in pneumatic tube systems (tube transport can rupture and aerosolize). This is an operational rule, but it shapes the planning of dumbwaiters, dedicated carts, and corridor routes during activation.
• Administration. Infusion bays must support closed-system drug-transfer devices (CSTDs), which USP <800> requires for HD administration when the dosage form allows, and supply PPE at the point of care.
• Waste. Trace-contaminated (yellow-stream) and bulk-hazardous (RCRA-regulated) HD waste need separate, clearly distinguished receptacles at every point of generation, with a compliant accumulation and disposal pathway.

A written Hazardous-Drug Safety Program is a deliverable, not an afterthought

USP <800> requires a designated person responsible for HD handling competency and a written program. For a new or renovated cancer center, that program is part of operational readiness and should be drafted in parallel with construction, not after move-in. Core components:

• Assessment of Risk. For each HD on the NIOSH list, the facility may either apply full <800> containment or document an alternative containment strategy and work practices. This assessment determines which spaces, equipment, and PPE each drug requires and is reviewed at least annually.
• Standard operating procedures for receiving, storage, compounding, CSTD use, administration, spill response, deactivation/decontamination/cleaning, and waste.
• PPE program. Chemotherapy-rated gowns (tested per ASTM standards), two pairs of chemotherapy-tested gloves, and respiratory and eye protection for spill and high-exposure tasks. PPE storage and donning/doffing locations must be designed into the rooms.
• Surface-contamination monitoring (wipe sampling). While <800> recommends rather than rigidly mandates a specific frequency, leading programs perform periodic wipe sampling to verify containment performance and trigger corrective action when marker drugs (e.g., common antineoplastics used as tracers) are detected outside acceptable thresholds.
• Medical surveillance of HD handlers and a documented exposure/incident response process.
• Spill-response capability — appropriately sized spill kits staged at every HD location, with trained responders and a documented procedure scaled to spill volume.

The program intersects construction because nearly every element implies a physical provision: a negative-pressure storage room, an HD refrigerator, PPE and spill-kit storage millwork, eyewash stations, dedicated waste rooms, and finishes that can be deactivated and decontaminated.

Surfaces, finishes, and deactivation drive material selection